FDA Draws a Hard Line on Compounded GLP-1 Drugs

May 15, 2026 - On April 30, 2026, the U.S. FDA announced a proposed rule to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulk Drug Substances List. The proposal closes the last regulatory pathway for large-scale outsourcing facilities to compound these GLP-1 receptor agonists from bulk drug substances.

The FDA reasoning is straightforward: with FDA-approved versions of all three drugs commercially available and no documented clinical need for compounded alternatives, the agency finds no justification for allowing 503B facilities to produce copies. This builds on enforcement actions already underway, including warning letters to online pharmacies selling compounded semaglutide and tirzepatide.

The Compounding Landscape: From Boom to Bust

The compounded GLP-1 market emerged during the acute shortages of 2023-2024, when Novo Nordisk and Eli Lilly struggled to meet explosive demand. At its peak, the compounded GLP-1 market was estimated at $3-5 billion annually, creating a parallel demand channel for GLP-1 API intermediates outside the traditional branded supply chain.

With the FDA proposed rule, this parallel channel is being dismantled:

• Bulk substance pathway closed: 503B facilities can no longer use bulk semaglutide, tirzepatide, or liraglutide for compounding
• Shortage exception eliminated: All three drugs removed from FDA shortage list
• 503A restrictions tightened: Individual compounding pharmacies face stricter enforcement

Redirected Demand: Branded Manufacturers Reclaim Market Share

The immediate consequence is demand redistribution back to branded manufacturers. Novo Nordisk and Eli Lilly, having invested tens of billions in capacity expansion, stand to recapture market share lost to compounders.

Winners - Branded API suppliers:

• Companies supplying semaglutide and tirzepatide API to Novo Nordisk and Eli Lilly will see increased volume
• Peptide synthesis specialists with existing contracts with major GLP-1 manufacturers benefit from volume growth
• Suppliers with GMP certifications aligned with FDA-approved manufacturing gain competitive advantage

Losers - Compounding-grade suppliers:

• Companies that pivoted to supply bulk peptide substances to 503B facilities face demand destruction
• Lower-cost, non-GMP peptide suppliers who entered during the shortage era must pivot or exit
• Intermediary distributors who built compounding-specific supply chains face inventory write-downs

Manufacturing Implications

The crackdown accelerates the shift from fragmented, small-batch production to centralized, large-scale GMP manufacturing.

Peptide Synthesis at Scale: Branded GLP-1 manufacturers require peptide APIs produced under strict GMP conditions. The solid-phase peptide synthesis (SPPS) process involves complex multi-step reactions requiring specialized resins, coupling reagents, and purification systems.

Quality Systems: Branded manufacturing requires comprehensive quality management, stability programs, and regulatory compliance documentation. API suppliers must demonstrate cGMP compliance and supply chain traceability.

Capacity Constraints: Rapid GLP-1 scaling has created bottlenecks from peptide synthesis resins to fill-finish capacity. Suppliers who invested early in capacity expansion are best positioned.

Looking Ahead: Oral GLP-1s

While the compounding crackdown consolidates the injectable GLP-1 market, the oral GLP-1 revolution introduced by Eli Lilly Foundayo (orforglipron) creates entirely new demand patterns. Oral GLP-1s utilize small molecule synthesis rather than peptide chemistry, opening opportunities for a different set of API suppliers.

The coexistence of injectable and oral GLP-1 therapies will create a dual-track supply chain: peptide specialists serving the injectable market, and small molecule manufacturers serving the oral market.

Strategic Takeaways

• Audit GLP-1 exposure: Assess how much revenue depends on compounding channels vs. branded manufacturing
• Invest in GMP capability: cGMP-certified peptide production facilities are best positioned for the branded demand shift
• Diversify modality exposure: The oral GLP-1 transition creates parallel opportunities in small molecule API manufacturing
• Monitor regulatory developments: The 503B proposal is not yet final and could be modified
• Engage branded manufacturers early: As Novo Nordisk and Lilly scale production, early supplier relationships create long-term advantages

Outlook

FDA proposed exclusion of GLP-1 drugs from the 503B bulks list represents a watershed moment. The regulatory crackdown will consolidate demand around branded manufacturers, reshape API demand patterns, and create new opportunities for suppliers aligned with large-scale GMP production. For B2B pharmaceutical suppliers: the era of compounding-driven GLP-1 demand is ending, and branded manufacturing at scale is accelerating.